Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percent of patients achieving major molecular response at baseline and at last visit
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Canada: Health Canada
CSTI571ACA09
NCT00171899
April 2005
June 2007
Name | Location |
---|